The deal will enable Synexus to further expand both its global network of clinical research centers - into the US, Asia and South America - and the range of therapy areas it focuses on.
The management team of Synexus has completed a buy-out in a private equity-backed deal in which Lyceum Capital have given up control of the clinical trial recruitment specialist.
The buy-out was supported by LDC, a U.K. mid-market, private equity company that is part of the Lloyds Banking Group. It is hoped this will enable Synexus to further expand both its branches of clinical research centers in the U.S, Asia, and South America and the range of therapy areas it focuses on.
“This will give us the firepower to continue expanding our international network and to broaden the number of therapy areas we offer to our pharma and CRO clients,” said Christophe Berthoux, CEO of Synexus. “We also need to continue to invest in our infrastructure and operations so that we carry on providing clients the best solution delivering thousands of patients and providing excellent quality data.
For the financial year ending December 2014, Synexus recorded revenues of $63m and profits of $12 million, representing a 140% increase in turnover since 2011. According to the company, its contracted order book currently stands at $216 million, an increase of $193 million since 2011. This growth has been achieved through a targeted buy-and-build strategy which has included launching new sites and acquiring four businesses since 2007, it stated.
Since being taken private in 2007, Synexus has expanded its international network from 13 to 25 dedicated research centers across eight countries. These centers are involved in more than 200 trials with 14,000 patients. Recent site openings have been in Hexham in the U.K. (a partnership with the National Health Service), Bochum in Germany, Bucharest in Romania, Poznan in Poland, and Sofia in Bulgaria. It also acquired a site near Cape Town in South Africa, and has a network of 25 affiliate sites.
By its tailored enrolment and retention strategies, Synexus aims to use its scale to deliver cost advantages and improve speed to market for new compounds, and it seeks to benefit from its investment in quality SOPs and dedicated scientific advisory boards for each therapeutic area.
LDC says it is backing the Synexus management to follow a strategy based on organic growth and acquisitions. The deal was led by LDC Director Ged Gould, who was supported by Investment Directors Simon Braham and Chris Wright. Gould will join the board of Synexus.
“We believe this is a particularly good sector as pharma continues to outsource their development activity. Synexus as the world leader in its field will benefit from this trend as well as the continued growth of the healthcare industry,” he commented. "Christophe and the management team have done a fantastic job in building an international network in recent years and we are eager to further support the business break into new markets as it targets opportunities in the US, South America and Asia."
For the full press release, click here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.